Finance

Lists
MGX:NASDAQ
Metagenomi Therapeutics Inc
US$ १.००
+०.६८%
(+०.००६८) 1D
US$ १.००
०.००% (०.००)
After hours
Closed: अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
US$ ०.९९
High
US$ १.०४
Low
US$ ०.९९
Mkt. cap
३.७९ करोड
Avg. vol.
१.५७ लाख
Volume
१.४७ लाख
52-wk high
US$ ३.९५
52-wk low
US$ ०.९६
EPS
-US$ २.४९
Shares outstanding
३.७८ करोड
No. of employees
११३
Open
US$ ०.९९
High
US$ १.०४
Low
US$ ०.९९
Mkt. cap
३.७९ करोड
Avg. vol.
१.५७ लाख
Volume
१.४७ लाख
52-wk high
US$ ३.९५
52-wk low
US$ ०.९६
EPS
-US$ २.४९
Shares outstanding
३.७८ करोड
No. of employees
११३
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
४ घण्टा पहिले
(CVCO) Risk Channels and Responsive Allocation
Foreign Policy Journal
Foreign Policy Journal
·
११ मिनेट पहिले
Strategy Inc. (NASDAQ: MSTR) Stock Surges 60% In Three Months As Bitcoin Treasury Expands, But Valuation Concerns Linger
Yahoo Finance
Yahoo Finance
·
११ घण्टा पहिले
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
MyStateline
MyStateline
·
१ दिन पहिले
Wall Street finishes its record-setting week with gains
About Metagenomi Therapeutics Inc
CEO-
Employees११३
Founded२०१६
HeadquartersEmeryville, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current US$ १.००
US$ ७.०० (+६००.००%)
Average
US$ ६.०० (+५००.००%)
Lowest
US$ ५.०० (+४००.००%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
US$ ७.००
+६००%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
US$ ५.००
+४००%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
US$ ५.००
+४००%
07/07/2026
Last report
२०२६ अगस्ट १०
Fiscal period
Q2 2026
-US$ ०.७३ / -US$ ०.५२
-४०.३८%miss
Revenue / Est. (USD)
-२.५७ लाख / २९.३३ लाख
-१०८.७६%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
८६.५९ लाख
३९.११ लाख
१२.४८ लाख
-२.५७ लाख
Cost of goods sold
२.५३ करोड
२.१५ करोड
१.९३ करोड
२.२५ करोड
Cost of revenue
२.५३ करोड
२.१५ करोड
१.९३ करोड
२.२५ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६२.१५ लाख
६७.७७ लाख
६५.३५ लाख
६०.०४ लाख
Operating expense
६२.१५ लाख
६७.७७ लाख
६५.३५ लाख
६०.०४ लाख
Total operating expenses
३.१५ करोड
२.८३ करोड
२.५८ करोड
२.८५ करोड
Operating income
-२.२८ करोड
-२.४४ करोड
-२.४६ करोड
-२.८८ करोड
Other non operating income
-२.०० हजार
-११.०० हजार
-१.०० हजार
३५.०० हजार
EBT including unusual items
-२.०६ करोड
-२.२५ करोड
-२.३० करोड
-२.७५ करोड
EBT excluding unusual items
-२.०६ करोड
-२.२५ करोड
-२.३० करोड
-२.७५ करोड
Income tax expense
-२.३४ लाख
३४.०० हजार
१०.०० हजार
-
Effective tax rate
१.१३%
-०.१५%
-०.०४%
-
Other operating expenses
-
-
-
-
Net income
-२.०४ करोड
-२.२५ करोड
-२.३१ करोड
-२.७५ करोड
Net profit margin
-२३५.५१%
-५७६.०२%
-१,८४७.६८%
१०,६९३.३९%
Earnings per share
-०.५५
-०.६०
-०.६१
-०.७३
Interest and investment income
२२.१४ लाख
१८.८४ लाख
१५.३९ लाख
१२.५६ लाख
Interest expense
-
-
-
-
Net interest expenses
२२.१४ लाख
१८.८४ लाख
१५.३९ लाख
१२.५६ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.१५ करोड
-२.३१ करोड
-२.३३ करोड
-२.७५ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू